| 0.7501 0.035 (4.92%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1 |
1-year : | 1.17 |
| Resists | First : | 0.86 |
Second : | 1 |
| Pivot price | 0.72  |
|||
| Supports | First : | 0.71 |
Second : | 0.62 |
| MAs | MA(5) : | 0.71 |
MA(20) : | 0.73 |
| MA(100) : | 0.87 |
MA(250) : | 1.19 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 23.5 |
D(3) : | 15.6 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 2.59 | Low : | 0.62 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NRSN ] has closed below upper band by 14.9%. Bollinger Bands are 67.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.82 - 0.82 | 0.82 - 0.83 |
| Low: | 0.71 - 0.72 | 0.72 - 0.72 |
| Close: | 0.74 - 0.75 | 0.75 - 0.76 |
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Sat, 25 Apr 2026
NeuroSense Therapeutics Transitions Chief Medical Officer to Advisory Role Ahead of Key PrimeC Milestones - The Globe and Mail
Fri, 24 Apr 2026
NeuroSense (NRSN) CMO steps down but stays on as advisor for PrimeC - Stock Titan
Mon, 06 Apr 2026
NeuroSense Granted Brazilian Patent Covering PrimeC Composition - PR Newswire
Fri, 03 Apr 2026
Nasdaq flags NeuroSense (NRSN) for bid price and $35M value shortfall - Stock Titan
Fri, 03 Apr 2026
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements - PR Newswire
Tue, 31 Mar 2026
NeuroSense Therapeutics (NRSN) director details options and restricted shares - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 2.621e+007 (%) |
| Held by Institutions | 18.6 (%) |
| Shares Short | 504 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.107e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -247.4 % |
| Return on Equity (ttm) | -2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 104.15 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -25.21 |
| Dividend | 0 |
| Forward Dividend | 594590 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|